Protea Biosciences

The partners aim to develop a diagnostic methodology for obtaining cancer cell molecular profiles to help guide immunotherapies.

The companies will market Proteos' protein production services alongside Protea's bioanalytical services.

The mass spectrometry services and instrument firm is working with a Yale pathologist to develop proteomic tests for solid tumors.

The test using proteomic mass spectrometry imaging to separate cancerous spots from benign moles was developed jointly by scientists at Protea and Yale.

Protea will purchase the research services firm with cash and Series A stock, but must first raise at least $10 million in debt or equity.

The partners will use mass spectrometry to study the occupational hazards of inhaling aerosols that are released during welding and electronic manufacturing.

NEW YORK (GenomeWeb) – Protea Biosciences and InSphero today said they will combine their 3D technologies into new products and services to be marketed to the pharmaceutical and biotechnology markets.

NEW YORK (GenomeWeb) – Protea Biosciences Group today said that it has signed an agreement to collaborate with the University of Southampton to identify biomarkers that may indicate a risk of developing Alzheimer's disease.

NEW YORK (GenomeWeb) – Protea Biosciences Group said today that it has undertaken a collaborative research effort with Memorial Sloan Kettering Cancer Center and the Dana-Farber Cancer Institute with an initial focus on lung cancer.

Pages

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.